Japanese Packaging Stock News

TSE:9104
TSE:9104Shipping

Elliott Pushes Mitsui O.S.K. Lines To Reassess Value And Capital Use

Elliott Investment Management publicly urged Mitsui O.S.K. Lines (TSE:9104) to pursue a more ambitious strategy. The activist investor is calling for an enhanced medium term plan and a premium market valuation for the company. Elliott signaled its intention to engage with management to seek changes it believes could increase shareholder value. Mitsui O.S.K. Lines is a major Japanese shipping group with exposure to global trade, energy transport, and logistics services. The sector is...
TSE:5019
TSE:5019Oil and Gas

Is It Too Late To Consider Idemitsu Kosan (TSE:5019) After Its Strong Recent Share Price Run?

Wondering whether Idemitsu KosanLtd at ¥1,488.5 is priced attractively or already reflects much of its story? This article walks through the key valuation angles to help you frame that question. The stock has moved 5.1% over the last 30 days and 26.2% year to date, with a 33.2% return over the past year and very large gains over 3 and 5 years. This naturally raises questions about how the current price compares with its fundamentals and risks. Recent coverage of Idemitsu KosanLtd has focused...
TSE:8473
TSE:8473Capital Markets

Does SBI Holdings (TSE:8473) Higher Dividend Signal Evolving Capital Priorities Or Strategy Shift?

Earlier in March 2026, SBI Holdings’ board approved a revision to its year-end dividend forecast to ¥75 per share, reflecting profit levels in its Financial Services Business, and later met again to consider converting a second-tier subsidiary into a direct subsidiary. The higher dividend forecast, equivalent to ¥150 per share before the stock split and ¥10 above the prior year, highlights management’s willingness to return more cash to shareholders while potentially reshaping the group...
TSE:4507
TSE:4507Pharmaceuticals

Shionogi (TSE:4507) Valuation Check After XOCOVA Post Exposure COVID 19 Approval

Shionogi (TSE:4507) is back in focus after Japan approved an expanded indication for its anti SARS-CoV-2 drug XOCOVA for post-exposure prophylaxis of COVID-19, grounded in positive global Phase 3 data. See our latest analysis for Shionogi. The XOCOVA approval has arrived alongside other pipeline updates, and the share price has reflected this with a 19.97% 90 day share price return and a 51.24% 1 year total shareholder return, suggesting momentum has been building over time. If you want to...
TSE:7733
TSE:7733Medical Equipment

Olympus (TSE:7733) Valuation Check After VISERA ELITE III Surgical Imaging Launch

Olympus (TSE:7733) is back in the spotlight after the U.S. launch of its VISERA ELITE III surgical imaging platform, a multi-specialty system that combines True 4K, 3D imaging, and software-driven workflow tools. See our latest analysis for Olympus. Despite the VISERA ELITE III launch putting Olympus back on investors' radar, the 1-day and 7-day share price returns of 2.25% and 4.45% sit against a weaker backdrop, with a 90-day share price return of a 28.84% decline and a 1-year total...
TSE:9449
TSE:9449IT

Assessing GMO Internet Group (TSE:9449) Valuation After GPU Cloud Alliance With Turing Inc.

Dividend cut and GPU cloud alliance put GMO internet group (TSE:9449) in focus GMO internet group (TSE:9449) has drawn fresh attention after announcing a reduced year end dividend, alongside a new capital and business alliance with Turing Inc. centered on the GPU cloud market. The dividend for the fourth quarter ended December 31, 2025 was set at ¥8.10 per share, compared with ¥10.00 a year earlier. The Turing Inc. agreement includes a share subscription and a 3.2 billion yen investment. See...
TSE:4307
TSE:4307IT

A Look At Nomura Research Institute (TSE:4307) Valuation After Guidance Update And Leadership Changes

Why Nomura Research Institute stock is back in focus Nomura Research Institute (TSE:4307) is drawing fresh attention after updating its consolidated earnings guidance for the fiscal year ending 31 March 2026, and announcing changes to its representative directors and broader management structure. See our latest analysis for Nomura Research Institute. The share price has reacted in a mixed way around these guidance and leadership updates. The 1 month share price return is 12%, while the 90 day...